Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Armata Pharmaceuticals, Inc.v398507_ex99-1.htm

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 6, 2015

 

 

AMPLIPHI BIOSCIENCES CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

         
Washington   000-23930   91-1549568

(State or other jurisdiction of

incorporation or organization)

 

 

(Commission

File Number)

 

 

(I.R.S. Employer

Identification No.)

 

4870 Sadler Road, Suite 300

Glen Allen, Virginia 23060

(Address of principal executive offices) (Zip code)

 

(804) 205-5069

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01 Other Events.

On January 6, 2015, AmpliPhi BioSciences Corporation (the “Company) issued a press release to provide updates to the Company’s shareholders on various matters. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

 

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:

Exhibit 99.1 – Press Release dated January 6, 2015

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

             
        AmpliPhi BioSciences Corporation
       
Date: January 9, 2015       By:  

/s/ David E. Bosher 

           

 David E. Bosher

 Chief Financial Officer

             

 

 

 
 

EXHIBIT INDEX

 

 

Exhibit No. Description
   
99.1 Press Release, dated January 6, 2015